- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03078829
The Relation of GnRH Treatment to QTc Interval in Transgender Females
The Relation of GnRH Treatment to QTc Interval in Transgender Female Youth: A Time Series Study
Background: The QT interval of the electrocardiogram (ECG), corrected for heart rate (QTc), is a measure of the duration of ventricular repolarization and is a widely used marker of ventricular arrhythmia risk. Testosterone has a shortening effect on QTc length, and the QTc interval in males is shorter than in females after the onset of puberty. Transgender female adolescents are treated with GnRH agonists or spironolactone that suppress endogenous testosterone secretion and might increase the QT interval sufficiently to increase the risk for malignant ventricular arrhythmias. There are no current guidelines regarding monitoring QTc interval in transgender females undergoing GnRH agonist treatment.
Objective: To assess the effect of GnRH agonist treatment on QTc interval in transfemale youth.
Methods: A quasi-experimental time series study of transgender female adolescent, seen at UCSF Child and Adolescent Gender Center (CAGC) during 2017-2019.
Specific aims:
To assess the impact of GnRH agonist treatment on QTc interval length in transgender female adolescent
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a quasi-experimental time series study, designed to examine the relation between GnRH agonist treatment for 6 months in transgender female youth and electrocardiographic change in QTc interval. Study subjects will be identified when visiting the UCSF Child and Adolescent Gender Center (CAGC). A baseline electrocardiogram (ECG) will be obtained in clinic before initiation of GnRH agonist treatment and at the 6 months follow up appointment.
Sampling scheme: Consecutive sample of transfemale patients presenting to UCSF CAGC (Child and Adolescent Gender Center) clinics meeting entry criteria, who consent to participate in this study
Recruitment strategy: The investigators will approach all transfemale patients with pubertal Tanner stage 4-5 who are ready to start GnRH agonist. From past experience in CAGC clinic, willingness of patients to participate in studies is high. The investigators plan that ECG will be available at clinic visits to further assist recruitment.
Retention strategy: Patients that are being treated in CAGC clinic are followed up every 3 months. Patients are very compliant with clinic visits as patients are eager to complete their transition. ECG is planned to be available at the 6 months clinic follow up visit.
Measurements: The investigators will assess QTc interval using a standard 12-lead ECG. The investigators will also measure serum levels of calcium, potassium and magnesium to rule out electrolyte abnormalities as a cause for QTc interval change, and testosterone, estradiol, LH and FSH levels to assess GnRH agonist effect. The laboratory analytes will be measured using standard procedures in place at the UCSF Laboratory, which is certified by Centers for Medicare and Medicaid Services, the California Department of Health Services, and the College of American Pathologists.
Outcome: A 12-lead ECG will be performed using standardized inspected equipment, at baseline and after 6 months of treatment. ECG reading and evaluation will be done by a board certified cardiologist. QT interval corrected for heart rate will be assessed using the Fridericia's correction (QTcF = QT/RR^0.33), which is currently preferred in accordance with the E14 ICH Guideline adopted by FDA and EMA in 2005. To minimize observer bias, the board certified cardiologist who will read the ECGs and determine QT interval length will be blinded to before or after status of GnRH agonist treatment.
Potential confounding variables: As this is a time series study with each participant serving as her own control, individual characteristics such as age, race and genetic factors are eliminated as confounding factors. Although this study has a within group design, typical disadvantages for such a research design, like learning effects, regression to the mean and secular trends do not seem to be relevant here. The investigators will need to monitor for factors that may change in the same participant over time and might act as a cofounders or mediators:
- Serum calcium, magnesium, and potassium levels
- BMI
- Starting other medications prolonging QT interval as: antihistamines, antiemetic or promotility drugs, azole antifungals, fluroquinolones, macrolides, antipsychotics, selective serotonin reuptake inhibitors.
Statistical issues
Analysis approach: A paired T test will be used for statistical analysis.
Data management plan: The investigators will use the Research Electronic Data Capture (REDCap) system to create forms (appendix 1) for entering study patients information. The investigators will use the REDCap installation, and will store the REDCap data on servers, located at the UCSF Minnesota Street data center. These servers are maintained behind a firewall in a secure server room; all servers are backed up regularly off-site.
Ethical considerations: This study involves obtaining an ECG, which has only minimal risk for the participants. Other information that is needed for this study, including blood tests and other measurements, is part of the regular clinical care in CAGC clinic. After the data is initially gathered and entered, it will be de-identified using a unique research identification number, to protect participant's privacy.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Transgender males to females in pubertal stage Tanner stage 4-5
- starting GnRH agonist treatment
Exclusion Criteria:
- Heart disease or arrhythmias at base line
- Electrolyte abnormalities at baseline (abnormal serum levels of calcium, potassium or magnesium)
- Failure to obtain informed consent from a parent or guarding or informed assent from a youth.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Trans female adolescents
All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
|
All patients will be treated with GnRH agonists
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in QTc Interval
Time Frame: 6 months
|
A 12-lead ECG will be performed using standardized inspected equipment, at baseline and after 6 months of treatment, difference in milliseconds will be calculates
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QTc interval > 450 milliseconds
Time Frame: 6 months
|
number of participants with QTc > 450 milliseconds at 6 months
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-19936
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gender Dysphoria
-
University Hospital, ToulouseCompletedGender Dysphoria, AdolescentFrance
-
Denver Health and Hospital AuthorityWithdrawn
-
University of Colorado, DenverRecruitingGender Dysphoria, AdolescentUnited States
-
Centre Hospitalier Henri LaboritRecruitingGender Dysphoria, AdultFrance
-
Hospices Civils de LyonCompletedGender Dysphoria Vaginoplasty SexualityFrance
-
Boston Children's HospitalChildren's Hospital Medical Center, CincinnatiRecruitingPuberty | Gender Dysphoria in Children | Bone DevelopmentUnited States
-
Karolinska University HospitalNot yet recruitingGender Dysphoria | Gender Identity | Gender Issues
-
Universitätsklinikum Hamburg-EppendorfUnknownGender Dysphoria | Gender Identity | Transsexualism | Gender Identity DisorderGermany
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCross Sex Hormonal Treatment in Adolescents With Gender Dysphoria
-
Universitätsklinikum Hamburg-EppendorfCompletedGender Dysphoria | Gender Identity | Transsexualism | Gender Identity Disorder | Gender IncongruenceGermany
Clinical Trials on Treatment with a GnRh agonists
-
Fundación Santiago Dexeus FontCompleted
-
EXcorLab GmbHMembrana GmbH; Nikkiso Co. Ltd; Nikkiso Medical GmbHTerminated
-
Wroclaw Medical UniversityCompletedCaries,Dental | Aerosol DiseasePoland
-
University Hospital, ToulouseUnknown
-
Mereo BioPharmaNovartisCompleted
-
University of AlcalaCompleted
-
USGI MedicalCentro Medico Teknon; Hospital Universitario Madrid SanchinarroCompletedTreatment of ObesitySpain
-
Penn State UniversityNational Institute of Mental Health (NIMH)Completed
-
Helsinki University Central HospitalCompletedFracture | ClavicleFinland
-
The First Affiliated Hospital of Zhengzhou UniversityUnknown